[ JLABS – Seoul Innovation QuickFire Challenge: Healthcare for the New Normal | Research Funding ]
Event details
| Date | 31.08.2020 |
| Category | Call for proposal |
Aim: While the implications of the pandemic are still unfolding, countries across the world are preparing for life in the “New Normal.” In this period of transition, forward-thinking innovations aiming to address healthcare challenges are needed more than ever. Through disruption, we must leverage data and health technologies to accelerate potentially life-saving ideas aiming to improve patient care through the uncharted times that lay ahead. That is why Johnson & Johnson Innovation—JLABS (“JLABS”), in collaboration with Seoul Metropolitan Government (“SMG”), Korea Health Industry Development Institute (“KHIDI”), Janssen Korea Ltd., is launching the Seoul Innovation QuickFire Challenge for Healthcare in the New Normal.
Up to two innovators with the best ideas aiming to address and enable potential healthcare solutions in the post-COVID era will receive up to KRW150,000,000 (approximately US$125,000) in grant funding, residency at the Seoul Bio Hub, and mentorship and coaching from experts at the Johnson & Johnson Family of Companies.
We encourage applications from innovators working on all aspects of health care within the “New Normal.” This includes:
Ingredients and vehicles for delivery that are backed by non-confidential pre-clinical / clinical data are preferred but not required (could be references to existing literature). Product should be available for commercialization in existing retail channels within 6-18 months.
Funding: KRW150,000,000
Duration: 1 year
Eligibility: Applicants may be individuals, entrepreneurs, academics, biotech researchers or an early-stage company that is less than 60 months old.
How to Apply: The one-step application process can be completed directly on JLAB’s application portal.
Deadline: 31-August-2020
Further information
Up to two innovators with the best ideas aiming to address and enable potential healthcare solutions in the post-COVID era will receive up to KRW150,000,000 (approximately US$125,000) in grant funding, residency at the Seoul Bio Hub, and mentorship and coaching from experts at the Johnson & Johnson Family of Companies.
We encourage applications from innovators working on all aspects of health care within the “New Normal.” This includes:
- Health technologies including big data, artificial intelligence, and block chain
- E-health platforms that can improve the patient journey, empowering decision making for physicians and leading to better patient outcomes
- Rapid diagnostics for early detection and monitoring of rare diseases – in particular for Pulmonary Hypertension (PH)
- Companion diagnostics for oncology
- Smart systems for vaccine distribution and patient adherence
Ingredients and vehicles for delivery that are backed by non-confidential pre-clinical / clinical data are preferred but not required (could be references to existing literature). Product should be available for commercialization in existing retail channels within 6-18 months.
Funding: KRW150,000,000
Duration: 1 year
Eligibility: Applicants may be individuals, entrepreneurs, academics, biotech researchers or an early-stage company that is less than 60 months old.
How to Apply: The one-step application process can be completed directly on JLAB’s application portal.
Deadline: 31-August-2020
Further information
- More information about the program is available here
- The application portal can be found here
- For any other questions, please contact the Research Office
Practical information
- General public
- Free